Hepatitis C (HCV) and Hepatitis Delta (HDV) Viruses in a Teaching Hospital in Southern Italy: What Is the Epidemiological Situation in the Era of New Drugs?

ABSTRACT: If the number of viral hepatitis infections is to be decreased worldwide, and the World Health Organization (WHO) elimination targets are to be achieved by 2030, this requires determining the burden of infection according to the WHO's test-and-treat approach. In 2014, the introduction of Direct-Acting Antivirals (DAAs) revolutionized the management of Hepatitis C Virus (HCV); another improvement came in 2020, when the use of bulevirtide (BLV) was authorized as a treatment for chronic Hepatitis D Virus (HDV) infection, showing good efficacy. The present observational study was carried out between 2019 and 2024. The diagnosis of viral hepatitis was carried out by routine assays. HDV typing was performed by Sanger sequencing and phylogenetic analysis. Overall, the HCV antibody prevalence was

SUBMITTER: Marascio N 

PROVIDER: S-EPMC12472279 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature